enGene Therapeutics (ENGN) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed enGene Therapeutics (ENGN) over the past year, gaining 4.9% versus a loss of 76.0%. enGene Therapeutics is the larger company by market cap ($119.3 million vs $112.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | PMVP |
|---|---|---|
| Share price | $1.78 | $1.49 |
| Market cap | $119.29M | $112.51M |
| 1-day change | +2.01% | -0.67% |
| YTD return | -80.29% | +19.20% |
| 1-year return | -75.98% | +4.93% |
| 5-year return | — | -93.78% |
| EPS (TTM) | $-2.07 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $1.91 |
| 52-week low | $1.40 | $1.02 |
| Distance from 52-week high | -85.47% | -21.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +84.83% | +181.88% |
| Average volume | 746.58K | 661.39K |
| Shares outstanding | 67.02M | 75.51M |
| Employees | 81 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed ENGN by 80.9 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
ENGN vs PMVP FAQ
Which is bigger, enGene Therapeutics or PMV Pharmaceuticals?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $119.29M compared with $112.51M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, ENGN or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and PMV Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for enGene Therapeutics and Biotechnology: Pharmaceutical Preparations for PMV Pharmaceuticals.